Evidence map›Paper›PMID 33073588›Full record

ArticleAmerican journal of physiology. Renal physiology2020

CDKL5: a promising new therapeutic target for acute kidney injury?

Mark de Caestecker

Abstract readEditorialComment
PubMed Publisher
In one paragraph

Article in American journal of physiology. Renal physiology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

1 author.

Mark de CaesteckerDivision of Nephrology, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee.

Funding

Vanderbilt O'Brien Kidney Center - Core D - Clinical and Translational CoreP30DK114809 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DE CAESTECKER, MARK P. · 2017 to 2021
$5.9M
Vanderbilt University Biomolecular Multimodal Imaging Center for 3-Dimensional Tissue MappingU54DK120058 · NIDDK · VANDERBILT UNIVERSITY · PI HARRIS, RAYMOND C. · 2018 to 2021
$5.7M
Matrix receptors in chronic kidney diseaseR01DK119212 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI BORZA, CORINA MARILENA, POZZI, AMBRA · 2018 to 2022
$1.7M
Mechanisms and therapeutic manipulation of retinoic acid signaling in Acute Kidney InjuryR01DK112688 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI DE CAESTECKER, MARK P. · 2017 to 2020
$1.7M
DOD | Congressionally Directed Medical Research Programs (CDMRP) W81XWH-17-1-0610HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 1R01DK112688HHS | NIH | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) 5P30 DK114809NIDDK NIH HHS R01 DK119212NIDDK NIH HHS U54 DK120058
6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Acute Kidney InjuryRhabdomyolysisHumansProtein Serine-Threonine KinasesSignal TransductionSOX9 Transcription FactorCDKL5 protein, humanProtein Serine-Threonine KinasesSOX9 protein, humanSOX9 Transcription Factoracute kidney injurycyclin-dependent kinase-like 5sex-determining region Y box 9therapeutics

Identifiers

PMID33073588

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.